key: cord-0744051-9sj8gj64
authors: Madamsetty, Vijay Sagar; Mohammadinejad, Reza; Uzieliene, Ilona; Nabavi, Noushin; Dehshahri, Ali; García-Couce, Jomarien; Tavakol, Shima; Moghassemi, Saeid; Dadashzadeh, Arezoo; Makvandi, Pooyan; Pardakhty, Abbas; Aghaei Afshar, Abbas; Seyfoddin, Ali
title: Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems
date: 2022-04-19
journal: ACS Biomater Sci Eng
DOI: 10.1021/acsbiomaterials.2c00026
sha: 30753ad1d58a629bf442a69564097e71500497d0
doc_id: 744051
cord_uid: 9sj8gj64

[Image: see text] Dexamethasone (DEX) has been widely used to treat a variety of diseases, including autoimmune diseases, allergies, ocular disorders, cancer, and, more recently, COVID-19. However, DEX usage is often restricted in the clinic due to its poor water solubility. When administered through a systemic route, it can elicit severe side effects, such as hypertension, peptic ulcers, hyperglycemia, and hydro-electrolytic disorders. There is currently much interest in developing efficient DEX-loaded nanoformulations that ameliorate adverse disease effects inhibiting advancements in scientific research. Various nanoparticles have been developed to selectively deliver drugs without destroying healthy cells or organs in recent years. In the present review, we have summarized some of the most attractive applications of DEX-loaded delivery systems, including liposomes, polymers, hydrogels, nanofibers, silica, calcium phosphate, and hydroxyapatite. This review provides our readers with a broad spectrum of nanomedicine approaches to deliver DEX safely.

The majority of human cells express glucocorticoid receptors (GRs) which can act as ligand-dependent transcription factors. These members of the nuclear receptor superfamily are present in the free form in the cytosol. The high-affinity state of the receptors for glucocorticoid (GC) binding occurs following the interaction of GRs with heat shock proteins ( Figure 1 ). 1−3 Various naturally occurring cortisols and their synthetic counterparts including dexamethasone (DEX) interact with the cytosolic GRs resulting in the dissociation of heat shock proteins from the receptors. 4 This dissociation leads to conformational changes in the GRs leading to entry into the nucleus. In the cell nucleus, GCs bind to the GC response elements resulting in changes in transcription ( Figure 1) . 5, 6 The molecular mechanism of GCs and their influences on the cells are not limited to the interaction and binding of the molecules with target sites in the genes but also include protein−protein interactions between the liganded GRs and other transcription factors in the cytosol. These interactions lead to changes in the capacity of other transcription factors that regulate transcription. 7 Other major targets for GCs are nongenomic in nature, including mitochondrial translocation, interactions with the plasma membrane, and signaling pathways. 8 The widespread cellular mechanisms involved in the action of GCs make these molecules suitable candidates for evaluation of their efficacy in various physiological processes, such as apoptosis and cell growth, as well as of their role in pathological conditions including inflammation. 8−10 The immunomodulatory effects of GCs such as DEX come from their impact on B cells and T cells via different molecular pathways. Their effect on B cells is through up-regulation of interleukin-10 (IL-10) as an anti-inflammatory cytokine and down-regulation of Toll-like receptor 7 signaling. GCs modulate T cells through regulating their cytokine expression and T cell receptor signaling. GCs are also able to inhibit the production of pro-inflammatory cytokines, including IL-1 and IL-6 as wells as prostaglandin E 2 and histamine. 11,12 Another major anti-inflammatory effect of these molecules occurs through the interaction of GRs and transcription factors such as NF-κB and AP-1 which act as critical modulators of several signaling pathways associated with B and T cell receptors. 11,13−15 Drug repurposing makes the process of drug discovery faster and more affordable. Drug repurposing has been contemplated through various methods including computational and experimental approaches. The diverse molecular pathways and mechanisms associated with the effect of GCs on cells make these molecules appropriate candidates for drug repurposing. 16 The high costs of drug development along with the essential needs for therapeutic agents to manage global health issues such as the novel 2019 coronavirus (COVID-19) pandemic have led researchers to repurpose available medications with low cost for widespread global applications. 14,17 Among the repurposed therapeutic molecules suggested for COVID-19, DEX has attracted considerable attention due to its low cost, various available formulations, well-known mechanism of action, and different routes of administration. 18, 19 This review summarizes some of the most attractive repurposed applications of DEX and its delivery systems, including liposomes, polymers, hydrogels, nanofibers, silica, calcium phosphate, and hydroxyapatite.

Anterior and posterior segments of the eye could be affected by various types of diseases. There are different pathological conditions associated with the anterior segment, including allergic conjunctivitis, pain, inflammatory reactions, glaucoma, Meibomian gland disease, and dry eye. On the other hand, common illnesses of the posterior segment comprise proliferative diabetic retinopathy, age-related macular degeneration (AMD), and macular edema. 20, 21 The most convenient approach for drug delivery to the eye for diseases associated with the anterior segment is topical formulations such as eye drops which include approximately 90% of available eye formulations in the market. Several disadvantages limit the wide application of such ophthalmic formulations, including nasolacrimal drainage, tear dilution, and low bioavailability. 22 Therefore, substantial attention has been directed to the intraocular administration systems with the ability to transfer sufficient concentrations of therapeutic molecules to the target site for long periods of time. This goal could be achieved by the application of intravitreal injections and ocular implants. 23 The main disadvantages of intravitreal injection that limit this administration route include patient compliance, retinal damage, hemorrhages, and endophthalmitis. Therefore, substantial efforts have been made to develop intraocular implants to maintain the drug concentration within the therapeutic levels for long periods of time. 23, 24 Corticosteroids have been recognized as one of the most efficient anti-inflammatory therapeutics. Since various diseases affecting the eye are among the inflammatory diseases, corticosteroids can be employed to manage the inflammatory conditions following ocular injuries or surgeries as well as conjunctivitis, uveitis, scleritis, episcleritis, redness, itching, and pain. 25−27 In addition to their anti-inflammatory effect, these medications have demonstrated a remarkable effect to inhibit the formation of new blood vessels. This anti-neovascular property is important for the treatment of some eye diseases related to blood vascularization including diabetic retinopathy (DR) and AMD. 28, 29 Moreover, corticosteroids have been proposed as suitable alternative therapeutic agents for antivascular endothelial growth factor (anti-VEGF) medications in diabetic macular edema (DME) following cataract surgery. 28 These applications make corticosteroids a key therapeutic agent in various eye diseases. Among corticosteroids used for the treatment of eye diseases, DEX has been considered as the most powerful. 30 This corticosteroid agent could be applied as a topical formulation, intravitreal injection, or implant. For topical formulations of DEX, ophthalmic solutions or suspensions could be prepared for different purposes. Ophthalmic solutions could be made by DEX salts with higher hydrophilicity (e.g., sodium phosphate and hydrochloride) while the suspensions are prepared with acetate and alcohol derivatives. The effectiveness of these formulations in the reduction of eye inflammation has been proved. 31 However, the risk of increase in intraocular pressure along the infections, uveitis, and cataract formation may lead researchers to seek novel drug delivery systems that enable the maintenance of the DEX therapeutic levels in the site of action. 32 Intravitreal injection of DEX (0.4 mg/mL) is available for the treatment of severe vitreous inflammation. 33 However, its short half-life following the intravitreal injection has led researchers to seek controlled release delivery systems for DEX. These efforts led to the preparation of Ozurdex as an intravitreal implant containing DEX (0.7 mg). The implant was prepared using the Novadur solid drug delivery system. This solid polymer system comprises poly(lactic-co-glycolic acid) (PLGA) as a biodegradable drug delivery carrier. 34, 35 Following the application of such a drug delivery system in the eye, PLGA degrades to lactic acid and glycolic acid, leading to the formation of carbon dioxide and water at the end. In other words, no residue will remain in the eye after the complete degradation of the drug delivery system. Ozurdex is a single-use, preservative-free, rod-shaped implant which is injected to the vitreous cavity through a 22-gauge applicator. This controlled delivery system leads to the maximum therapeutic effectiveness 2−3 months post implementation while the maintenance of therapeutic doses in the target site has been observed up to six months after the injection ( Figure  2 ). 34−36 One of the major advantages of this implant is its application in vitrectomized eyes where the conventional intravitreal injections lead to a rapid clearance of the drug due to the short half-life. 37 In order to assess the efficacy and safety of Ozurdex in eyes with vision loss due to macular edema (ME) associated with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), a randomized, shamcontrolled trial of the DEX implant was carried out called the GENEVA study. The global evaluation of implantable DEX in retinal vein occlusion with macular edema (GENEVA) study was designed with a total of 1267 patients receiving a single injection of 0.7 mg of DEX implant, 0.35 mg of DEX implant, or sham. The results of this study demonstrated that both DEX implant groups improved the best-corrected visual acuity (BCVA) in the patients compared with sham at 30−90 days post implementation. 38 There are some contraindications for Ozurdex, including hypersensitivity to the drug or the delivery system as well as glaucoma or ocular infections. 39 The side effects of implantation of Ozurdex consist of increased intraocular pressure, retinal detachment, endophthalmitis, and vitreous hemorrhages in 2−5% of the patients. 35, 40 In summary, DEX could be used to manage various anterior and posterior ophthalmic diseases with effectively designed drug delivery systems.

JOINT DISORDERS The global prevalence of rheumatic and musculoskeletal diseases (RMDs) is rising, with osteoarthritis (OA) and rheumatoid arthritis (RA) the most frequent joint disorders worldwide. 42,43 OA is primarily associated with aging, obesity, joint traumas, and genetic disorders, whereas RA is an autoimmune disease, which may begin at any time in life. 44 Both diseases are typically painful, lead to disability with a significant impact on the quality of life, 45,46 and are most prevalent in women. 47, 48 Currently, there is no effective treatment for OA, 49 and to reduce the burden of OA, patients are recommended to have regular exercise and use antiinflammatory medications. 50,51 In the case of RA, GCs and disease-modifying anti-rheumatic drugs, mostly methotrexate, are used to reduce the symptoms. 52 Corticosteroids, including DEX, have been considered potent anti-inflammatory agents for the treatment of RMDs and have been used for more than 50 years to treat OA and RA pain. 53 A number of preclinical and clinical studies have demonstrated that DEX inhibits inflammation and joint tissue damage. 17,18,20,21 For instance, a clinical study assessed patients' positive functional mobility and pain relief when DEX was administered by applying phonophoresis with ultrasound on knee OA. 54 Furthermore, low-dose sustained DEX delivery in combination with an agarose hydrogel carrier has demonstrated chondroprotection in the presence of IL-1 in canine chondrocytes in vitro and improved in vivo outcomes in a canine model. 55 Moreover, meta-analyses were performed to evaluate the effects of injected DEX on pain and recovery after total knee arthroplasty in patients. According to different studies, DEX decreased postoperative pain when compared to placebo groups. 56,57 In addition, DEX and growth factors play a pivotal role in stimulating mesenchymal stem cell (MSC) differentiation toward chondrogenic, osteogenic, and adipogenic lineages. 58,59 However, to drive MSC differentiation toward specific lineages, it has been shown that the amount of applied DEX is critical. For instance, higher amounts of DEX (more than 100 nM) might diminish human synovial MSCs' potential to differentiate into the chondrogenic lineage but instead promote adipogenesis; however, when used up to 10 nM, chondrogenesis is remarkably promoted by extracellular matrix protein synthesis. 60 However, despite all of the advantageous DEX characteristics, its usage for RMDs has become controversial due to its potentially harmful side effects. 61,62 A comprehensive review of biological processes that can be negatively affected by DEX has been recently published, including clinical data and animal model studies. 61 Even though the precise mechanism of DEX action on cellular pathways is still not well understood, this review highlights the importance of the dosage and duration of DEX administration as crucial factors that can lead to either beneficial or harmful effects. For example, it has been shown that repeated DEX injections at high clinical doses can lose their analgesic drug effects but cause a variety of side effects such as hypertension, psychological disturbance, adrenal gland depression, osteoporosis, and susceptibility to infections. Also, it has been reported that even low doses of DEX are cytotoxic, as they cause chondrocyte death and reduce cell proliferation. Moreover, it has been reported that repeated intra-articular corticosteroid injections (every 3 months for over a 2 year period) are associated with cartilage loss and degradation, according to radiographic OA progression. 63 A cohort of participants with an intra-articular injection of corticosteroids was compared with another cohort of mild to moderate knee OA (684 participants in total). Two parameters were reported for the evaluation of disease progression: (a) an increase in Kellgren and Lawrence grade, which is a radiographic OA scoring system, and (b) a decrease in joint space width. Both measures revealed worsening of OA symptoms after continued injections of corticosteroids, which is associated with an increased risk of OA progression. 63 Taken together, the positive role of DEX on joint tissues remains conflicting and confounded in many studies and, therefore, worthy of further investigations. 64 Considering the history of DEX use in OA and RA, the beneficial effects of corticosteroids for intra-articular administration occur at low doses (around <2−3 mg/dose or 8−12 mg of cumulative total dose), whereas higher doses are associated with cartilage degradation. 65 Thus, the full understanding of the therapeutic potential of DEX requires many more controlled studies and optimizations for further clinical applications. 61

CANCER THERAPY Drug repurposing is an emerging research field for the treatment of different types of cancers. 66,67 DEX as a synthetic GC is widely used for treating severe inflammation and autoimmune diseases. It exerts this effect by binding to the ubiquitous intracellular GC steroid receptor in the cytoplasm of most cells and can particularly affect lymphocytes and macrophages. 68 In the field of cancer therapy, DEX can decrease the secondary inflammatory response via interfering with the production of IL-1 and TNF-α. 69 Therefore, the antiinflammatory nature of DEX can reduce cancer treatments' side effects, including chemo-, radio-, and immunotherapies. According to the recent literature, DEX has been used as a pretreatment coadministration agent to optimize the treatment of various cancer types, such as breast cancer, 70 85, 86 One of the most common DEX applications is to improve the treatment of multiple myeloma (MM), a malignancy of B cells, to reduce the immunoglobulin levels. 87, 88 Lenalidomide (an immunomodulatory derivative of thalidomide) has a relatively great potential due to its anti-MM activities when used in association with DEX, for both in vitro and in clinical studies. This approach has the Food and Drug Administration's (FDA) approval for MM relapsing therapy after prior treatment. Lenalidomide−DEX combination improves the success of MM treatments due to extending its progression time and survival rates. 89−91 Recently, Garderet et al. also studied the efficiency and safety of weekly administrated oral pomalidomide/cyclophosphamide (PCD)/DEX as a secondline treatment in a MM population cohort. In this study, all patients received 4 mg of pomalidomide, 300 mg of cyclophosphamide, and 40 mg of DEX within a spaced-out schedule. They concluded that this combination was highly effective and safe to be considered as having a great potential for MM therapy. 92 DEX is often used as a pretreatment drug in breast cancer patients before chemotherapy to prevent allergic reactions and chemotherapeutic side effects. 93 To prevent stomatitis in breast cancer patients, DEX-based mouthwash has been assessed. In this study, 86 patients received 10 mg of everolimus plus 25 mg of exemestane with 10 mL of an alcohol-free oral solution of DEX at 0.1 mg/mL per day for 8 weeks. The results showed that prophylactic usage of a DEX oral solution causes a gradual reduction of stomatitis incidence and severity. 94 In another study, it was shown that pretreatment with DEX also improves the chemotherapeutic functions and increases the cancer therapy efficacy against breast tumors and metastases. Martin et al. studied murine breast cancer treatment by cisplatin-loaded polymeric micelles and reported that DEX could normalize vessels and increase nanocarriers' penetration by enhancing the interstitial hydraulic conductivity. 70 In 2018, Ge et al. investigated coadministration of DEX and pemetrexed, which is used as an antineoplastic agent, in lung cancer treatment. In the in vitro study on nonsquamous nonsmall cell lung cancer (NSCLC), squamous human bronchial epithelial cells, and pleural mesothelioma cells, there was an induction in the insensitivity of the senescence associate secretory phenotype (SASP) to the DEX combination with pemetrexed. Senescent cells expressed SASPs which are involved in inflammatory cytokines and chemokine production. This expression profile ultimately altered the tumor microenvironment, suggesting that DEX can the optimize cellular therapeutic response by changing SASP expression and the IL-6, IL-8, MCP-1, and IL-1β cascade. This results in inhibition of pemetrexed-induced cellular senescence and insensitivity to pemetrexed. 83, 95 In another study on lung cancer, it was found that DEX can suppress the growth of NSCLC xenograft tumors by inducing estrogen sulfotransferase and reducing the estradiol levels in tumor models. These results suggest that DEX can be used as an anti-estrogenic agent for lung cancer therapy. 84

APPLICATIONS Using drugs in tissue engineering can lead to the development of bioactive scaffolds that regulate the rate of cellular proliferation and differentiation. 96 One of the drugs used in tissue engineering applications is DEX, which can affect cellular behaviors such as proliferation, mitosis, growth, gene expression, and osteogenic differentiation of MSCs in vitro. 97−99 DEX can bind to the GC inside the cytoplasmic matrix and act as an osteogenic factor. The controlled release of DEX can improve osteogenic differentiation and increase osteocalcin gene expression. 100, 101 Indeed, DEX incorporated scaffolds have the ability to increase the concentration of proteins such as alkaline phosphate (ALP), an important osteogenic marker, osteocalcin expression, and biomineralization. 102 both in vitro and in vivo. They found that DEX nanoparticles (NPs) were biocompatible and induced osteogenic differentiation in rat bone marrow-derived MSCs compared to NPs without DEX supplementation. DEX could also improve the regeneration of calvarial defects in vivo. 105 Besides, Panek et al. investigated the optimal concentration of DEX released under perfusion force for bone tissue engineering applications and suggested the concentration of 4 × 10−4 M with a perfusion rate of 0.1 mL/min was beneficial for bone tissue engineering and osteogenic differentiation in vitro. 106 DEX can also be used in engineered cartilage constructs to prevent collagen degradation in response to IL-1α and shield them from the negative impacts of IL-1α. Other benefits include reduction in degradation of proteoglycan, preservation of biosynthesis of tumor necrosis factor-α (TNF-α) and mechanical damage-exposed cartilage constructs, action in proanabolic and anti-catabolic processes, 107 assistance of the functional maturation of MSCs, and protection and preservation of cellular properties during a long-term culture. 108 DEX, as an anti-inflammatory reagent, can suppress activated macrophages 109 and induce chondrogenic differentiation through modulating the synthesis of proteoglycan. 110 Westin et al. suggested incorporating DEX, diclofenac sodium, and gallic acid in polysaccharide-based thermosensitive hydrogels as a suitable injectable material for the restoration of damaged osteoarthritic joints. 110 In addition to cartilage 60,107,111,112 and bone regeneration, 113−116 the application of DEX has been considered for adipose tissue engineering to preserve the stability of adipose tissue reconstruction. As such, the sustained release of DEX can improve both adipogenesis and angiogenesis in the constructs. 117 For instance, Jia et al. studied a magnetic hyaluronic acid (HA) nanosphere system which can control the release of DEX as an adipogenic factor by an external magnetic field for adipose tissue engineering. 118 The results demonstrated the potential of this system for adipose regeneration and viability of human adipose-derived stem cells. Moreover, DEX has been used as a myogenic differentiation agent in several investigations. It can improve the fusion of myogenic cells and increase the expression of dysferlin and other myogenic transcription factors 119 that regulate myogenesis. 120 It has also been shown to regulate the endogenous expression of insulin-like growth factor (IGF)-II during muscle differentiation. 121 Han et al. investigated the effects of DEX on myocyte differentiation in two different stages of development, the myoblast and myotube phases. The results indicate that at the myotube stage, DEX treatment can lead to a thinner myotube, induction of the atrogin-1 expression, and inhibition of the amount of myosin heavy chains. However, DEX has an opposite role at the myoblast stage by increasing the myotube's diameter, decreasing the expression of the atrogin-1, and raising the amount of myosin heavy chain. 122

On December 8, 2019, the lethal outbreak of a coronavirus strain named COVID-19 started in the Chinese province of Hubei. 123, 124 It spread rapidly worldwide and turned into a huge pandemic. 125, 126 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) attaches to the two well-known cell surface receptors ACE2 and CD147 through spike glycoproteins. 127 However, it seems that ACE2 is its main receptor involved in cytokine storm and pathogenesis there-of 128 while CD147, a transmembrane glycoprotein and metalloproteinase inducer, is another potent receptor in host cells involved in SARS-CoV-2 virus invasion. 129 Besides, following cell target entry, the aryl hydrocarbon receptor is activated and promotes inflammation, fibrosis, and thromboembolism. 130 It is demonstrated that spike-CD147 blockage decreases the virus virulence's pathogenesis. However, CD147 is overexpressed in other pathological conditions such as tumors, diabetes, and inflammation. 131, 132 Therefore, it explains further complicated reactions and comorbidities in COVID-19 patients who have underlying diseases. Notably, the moderate effectiveness of the anti-malaria drug chloroquine in COVID-19 patients is partly due to the involvement of CD147 in the pathogenesis of both COVID-19 and malaria. Interestingly, this receptor is responsible for the interaction of the malaria parasite on red blood cells. Moreover, coadministration of DEX and hydroxychloroquine decreases the rate of mortality compared to hydroxychloroquine alone. 133 Notably, the effective dose and half-life of DEX are higher than other corticosteroids such as prednisone, methylprednisolone, and hydrocortisone, respectively. 134 However, administration of DEX in hospitalized hypoxic COVID-19 patients showed less clinical status, longer hospital stay, and more need for a ventilator compared to methylprednisolone. 135 The superior effect of methylprednisolone points back to higher lung penetration of methylprednisolone than DEX. 136 The administration of DEX is not recommended at the primary stage of the disease. In other words, the body needs to combat the SARS-CoV-2 virus at the first stage, and therefore, the administration of DEX will suppress the immune system and decline the body's defense. However, when the disease progresses and a cytokine storm is started, corticosteroids would be promising. The World Health Organization recommends 6 mg/day of DEX for up to 10 days in COVID-19 patients. 137 However, its adverse reactions such as psychiatric effects, hyperglycemia, hypokalemia, secondary infections, mucormycosis, gastrointestinal hemorrhage, and prolongation of viral clearance should be monitored. 138 DEX, at the 6 mg/daily dose, did not change the incidence of cardiac arrhythmia compared to conventional therapeutics. 139 It postponed the viral RNA clearance in patients with mild symptoms compared to patients that did not receive DEX. 140 In fact, there are controversial outcomes derived from clinical trial studies related to the efficacy of corticosteroids in COVID-19 patients. Although a meta-analysis study in China shows an increased risk of mortality and multiorgan dysfunction, 141,142 some other studies indicated a decline of mortality in patients. 143−145 It is demonstrated that the mechanism of action of DEX in COVID-19 patients is partly related to the reversion of histone deacetylase activation. In fact, it acts through two genomic and nongenomic mechanisms. In other words, SARS-CoV-2 suppresses the transportation of HDAC2 to the nucleolus by CREB, AP-1, and NF-κB activation and disturbs cytokine responses and inflammation. 146 Moreover, Wang et al. reported that DEX decreases CD147 expression through suppression of the NF-κB signaling pathway. Notwithstanding, inflammation led to CD147 up-regulation and higher availability of receptors for the SARS-CoV-2 virus. DEX treatment also led to down-regulation of CD147 to decrease virus attachment, virulence, and the expression of TNF-α and IL-6 as regulated by NF-κB. 147 

ACS Biomaterials Science & Engineering pubs.acs.org/journal/abseba Review derived from the activation of two ACE2 and CD147 receptors through the anti-inflammatory cytokines of IL-10 and lipocortin-1. 148 It is noteworthy that a bioinformatics study on transcriptomic data showed that DEX is not involved in IL-6 signaling. 149 There are studies reporting DEX's ability to downregulate 150 and up-regulate ACE2 expression. 151, 152 This has a double-edge effect on COVID-19 because the body needs ACE2 at a baseline level to protect lung and other tissues from damage, whereas the up-regulation of ACE2 makes it ideal for higher levels of virus attachment and entrance. It is noteworthy that the SARS-CoV-2 virus decreases the levels of ACE2 availability, and therefore, ACE2 reduction to baseline will enhance tissue damage protection derived from virus entrance. This also prevents the signaling pathways involved in a cytokine storm. Specifically, consideration should be given to decreasing the C-terminal cleavage site of ACE2 and not the whole ACE2 expression. 153 Findings confirm the efficacy of DEX in decreasing the mortality and duration of hospitalization among COVID-19 patients receiving respiratory support and not in the mild form of COVID-19. 139 It is noteworthy that there was no significant difference between two doses of 12 and 6 mg/daily in the alive day number without life support. 154 High doses of DEX applied through nongenomic mechanisms combine to the integrin and activate focal adhesion kinas. It, at the high dose, rapidly decreases inflammation through the alteration in the movement of the ionic channel of Ca 2+ and Na + . 155 Moreover, the effect of DEX is dependent on the stage of the COVID-19. At the early stage of inflammation, it decreases exudation of inflammatory cells, vasodilation, and phagocytosis, and in the severe condition of inflammation, it inhibits fibrosis through the diminishing of fibroblast proliferation. 130 To sum up, it seems that DEX would be a promising medication to modulate COVID-19 in the middle and advanced stages of the COVID-19 infection and not in patients who have mild symptoms and are in the virus proliferation phase of COVID-19 with low inflammation. However, the particular lung cells in COVID-19 are glucocorticoids resistant. 156 7. DEXAMETHASONE DELIVERY SYSTEMS 7.1. Lipid-Based Nanostructures. Several medicinally active small molecules are biologically less potent because most of them are water-insoluble, resulting in severe side effects. 157, 158 Recently, lipid-based nanoparticles (LNPs) have become versatile platforms for drug carriers of biologically active small molecules. 159−161 LNPs have many advantages over other NPs, such as ease of preparation, high thermal stability, low production costs, high loading capacity, preparation from natural sources, and being amenable to large-scale industrial manufacturing. 162−165 For example, recently, scientists have developed modified LNPs using a positively charged chitosan loaded with DEX. This nanosystem showed promising ocular bioavailability by enhancing the retention time and permeation into the cornea. This strategy improved the status quo strategies for the treatment of ocular disease. 236 DEX has been established as an effective treatment strategy for a variety of inflammatory diseases, including arthritis. However, its usage is limited due to poor water solubility, tissue distribution, and in vivo bioavailability. To overcome these limitations, researchers have developed DEX palmitate-loaded lipid-based mixed micelles containing sodium glycocholate/egg yolk lecithin for the treatment of RA with effectiveness. 237 In summary, LNPs such as SLNs, liposomes, and niosomes, comprised of DEX, provide excellent benefits in treating various diseases and may have the potential to develop future clinical treatment options. 238 7.1.1. Liposomes. Liposomes are well-established lipidbased drug delivery systems. 239, 240 Even though liposome discovery dates back to the 1980s, it has recently become more attractive following FDA approval of several liposomal-based therapeutics, and many are in clinical trials. 241, 242 Among several types of nanoformulations, the liposomal-based drugs were approved by the FDA to treat various diseases, including cancer. 241, 243, 244 Liposomes have a wide diversity of applications in various disease treatments caused by viruses, bacteria, or protozoa. 245, 246 Even though liposomes are the most widely used LNPs, 247 their therapeutic outcomes can be further improved with several surface modifications. 247 Both hydrophobic and hydrophilic drugs can successfully be loaded in liposomes, and DEX-loaded liposomes are well-established in preclinical studies (Table 1) . 248 Recently, researchers developed DEX-loaded stealth liposomes for improving the anti-inflammatory effects of DEX in the treatment of RA. They report that DEX-loaded liposomes have a preferential accumulation at inflamed joint sites with extended blood circulation time with improved results in reducing the swelling of the inflamed joint tissues by suppressing the levels of the proinflammatory cytokines TNF-α and IL-1β, in joint tissues in RA (Figure 3 ). 249 7.1.2. Solid Lipid Nanoparticles. Solid lipid nanoparticles (SLNs) are a rapidly developing field of nanotechnology with numerous applications in research and clinical medicine. 250, 251 In SLNs, the solid lipid core comprises triglycerides, fatty acids lightened by the interfacial surfactant layer. 251 SLNs are lowtoxic sphere-shaped colloidal NPs with average sizes ranging from 50 to 100 nm. These SLNs offer the development of new, efficient formulations due to their exceptional size-dependent properties. Further, SLNs hold remarkable potential for controlling and site-specific drug delivery and, hence, have widely fascinated scientists. 252 It is important that these SLNs are also used to develop several anti-inflammatory drugs, including DEX. 253, 254 For example, scientists developed SLNs to deliver DEX and butyrate (DxCb-SLN) to improve antiinflammatory activity with low doses to treat inflammatory bowel disease. 167 These SLN formulations showed significance in inducing in vitro inhibition of cell adhesion and significantly reducing pro-inflammatory cytokines (IL-1β and TNF-α) in both in vitro and in vivo settings. 167 Another study established novel DEX-loaded SLN formulations for the lung-targeting delivery of DEX acetate upon intravenous administration. They developed dexamethasone acetate (DXM)-SLNs with an average size of 552 ± 6.5 nm, 8.79 ± 0.04% of drug loading capacity, 92.1 ± 0.41% entrapment efficiency, and initial burst in vitro release. A 17.8-fold greater area under the curve of DXM-SLNs was accomplished in comparison with pristine DEX. 255 7.1.3. Other Lipid-Based Nanoparticles. Similarly, several other lipid-based NPs, such as nanostructured lipid carriers (NLCs), lipid nanocapsules (LNCs), polymer lipid NPs, and lipid-based micelles, were developed to deliver various drugs. 256 262 This NLC formulation showed a 5fold reduction of TNF-α production over free DEX. 262 Similarly, other lipid-chitosan, 263 lipid-hydrogel, 264 lipidalginate, 265 and polymeric-based 266, 267 lipid NPs were developed to deliver DEX. 7.2. Polymeric Platforms. Polymeric NPs represent additional drug delivery systems with a vast potential for targeted and localized delivery of drugs/genes. 268−276 Natural polymers such as chitosan, arginine, dextrin, poly(glycolic acid), polysaccharides, poly(lactic acid), and hyaluronic acid have been used for developing polymeric drug delivery systems. 277 Some synthetic polymers, including poly(2-hydroxyethyl methacrylate), poly(ethylenimine)s, poly(Nisopropylacrylamide)s, and dendritic polymers, have also been used for polymeric-based NPs' development. 278 Polymeric NPs are excellent micro-/nanocarriers for drugs/genes that are loaded through either encapsulation or covalent bonding for a controlled release of loaded therapeutic cargoes in in vivo settings in a highly selective manner. 279−285 Notably, polymers can deliver both hydrophilic and hydrophobic drugs and the convenience of administering to patients through diverse pathways, such as oral, ocular, nasal, and inhalation. 286−289 These maintain the therapeutic dose of drugs in plasma for more extended periods by controlling their release. 290, 291 GCs are extensively used for the treatment of several diseases, such as RA, systemic lupus erythematosus, asthma, lymphoid neoplasia, and eye and skin inflammations. 292 Additionally, DEX and α-tocopheryl succinate are being used to avoid chemotherapy-induced ototoxicity. However, they have low water solubility and present severe systemic side effects upon prolonged use. Researchers have developed incorporated polymeric NPs to lower cisplatin-induced toxicity in both in vitro and in vivo settings. 293 A similar study was performed to assess the possible protective effect of DEXloaded PEG-coated polylactic acid NPs against cisplatininduced hearing loss. 294 In another study, DEX-loaded polycaprolactone-PEG-polycaprolactone NPs were used to improve the anti-inflammatory effects of DEX. 295 7.2.1. Chitosan Nanoparticles. Chitosan is a cationic natural polysaccharide consisting of D-glucosamine and Nacetyl D-glucosamine groups linked by β-(1−4) glycosidic bonds. 296 It is obtained by alkaline deacetylation of chitin, the second most abundant polysaccharide in nature. 297, 298 Among its properties, biocompatibility, biodegradability, and nontoxicity are the most attractive, while antimicrobial activity and muco-adhesiveness add additional advantages. 299−302 DEXloaded chitosan-coated BSA polydopamine-layered NPs provide the potential to modify adhesive and transferable free-standing films. 303 Additionally, chitosan has functional groups, such as amino and hydroxyl groups, that allow it to easily react and functionalize. 302, 304 Due to all of the above, chitosan and its derivatives have been used in a wide variety of biomedical applications, such as tissue engineering, wound healing, and drug delivery systems. 300, 305 Chitosan-based systems have also been used for the controlled release of DEX in recent years. 306−308 The release of DEX using platforms, such as membranes, fibers, and micro,/nanoparticles of chitosan or its derivatives, has been one of the most studied applications in ocular disease. In almost all of the studies, the incorporation of DEX in a chitosan matrix enhances the effects and favors the permanence of drug in the ocular regions. Self-assembled NPs obtained from a series of DEX−chitosan glycol conjugates turn out to have very good biocompatibility in human colonic epithelial cells (HCEC), L-929, and RAW 264.7 cells after 24 h, and the controlled release of DEX continues up to 48 h without the drug losing its anti-inflammatory properties. 309 Similarly, other DEX-loaded self-assembled succinyl-cholesterol chitosan particles released 50% of DEX in 2 h and 95% after 24 h and were not cytotoxic. The released DEX elicited an anti-inflammatory activity comparable to that of pure DEX treatment. 310 7.2.2. Polylactic Acid Nanoparticles. Polylactic acid (PLA) is categorized as an aliphatic polyester because of the ester bonds that connect the monomer units. 311 PLA-based NPs have a key role in the biomedical field with a wide range of applications. 312−315 PLA has been recognized as a multipurpose material with high-biodegradability and -biocompatibility properties and approved for use by the FDA. 316 PLA has been used in suture threads, bone fixing screws, medical devices, and drug delivery vehicles. 317 The benefit of PLA is that it naturally degrades in situ through a hydrolysis mechanism (water molecules break the ester bonds that constitute the polymer backbone). This avoids the necessity for further surgeries to remove medical devices (e.g., sutures), lowering health system costs and benefiting patient recoveries. 318 PLA-based NPs are used to deliver several drugs, including DEX. For example, a single dose of DEX-loaded PEGfabricated PLA NPs diminishes cisplatin-induced hearing loss with its prolonged sustained release property. Importantly, coumarin 6-loaded NPs entered round window membrane (RWM) quickly and accumulated on the organ of Corti, ganglion cells, and stria vascularis in guinea pigs. 319 Researchers synthesized DEX bioconjugated poly-(phenylacetylene) and poly(phenylacetylene-co-acrylic acid) NPs to induce apoptosis of human tumor cells. 320 DEX-loaded PLA NPs are also used in tissue engineering. Recently, scientists developed DEX-loaded PLA/PCL nanofibrous scaffolds with mesoporous silica NPs and used in bone tissue engineering applications. 105 Another group developed a similar approach for the treatment of tissue engineering applications. In their study, a DEX-loaded scaffold of PLA and mesoporous silica was fabricated with chitosan through electrospinning and used for bone tissue engineering application. 101 7.2.3. Poly(lactic-co-glycolic acid) Nanoparticles. Poly-(lactic-co-glycolic acid) (PLGA) is another biocompatible and biodegradable polymer used for making polymeric NPs. 321 The US FDA has approved PLGA NPs for use in the delivery of drugs, proteins, peptides, imaging agents, and small molecules owing to their sustained and controlled release properties with negligible toxicity to cells and tissues. 322 With the use of PLGA NPs, the limitations of poor tissue permeability and low aqueous solubility are resolved. 322 Notably, PLGA NPs have demonstrated no immunogenicity in vivo, which is precarious for the safety of drug delivery systems. PLGA NPs are tunable and malleable so that their surfaces can be easily altered with other polymers, including poly(β-amino esters), PLA, and chitosan, to improve the drug loading and delivery efficacy. Additionally, PLGA NPs can be fabricated with targeting ligands such as small peptides, proteins, small molecules, or antibodies. 323 PLGA NPs mediated delivery of anti-inflammatory drugs is now well-established in various diseases. 322, 324 Recently, scientists found a simple and efficient method for loading DEX into the PLGA NPs and evaluated the resulting characteristic properties. They evaluated the drug loading efficiency, encapsulation efficiency, and cumulative release and reported improvement compared to stand-alone drugs separately. 325 Goḿez-Gaete et al. developed a similar optimized method for DEX loading of biodegradable PLGA NPs using a solvent evaporation technique. The size and zeta potentials of empty and DEX-loaded NPs were not altered, and a high drug encapsulation was attained using 100 mg of PLGA in a mixture of 1:1 (v:v) acetone−dichloromethane and 10 mg of DEX. 326 Recently, investigators developed novel biodegradable PLGA NPs containing both ovalbumin and DEX NP[OVA+DEX] to induce antigen-specific immune tolerance.

Interestingly, in their findings, NP[OVA+DEX] treated immature dendritic cells did not mature to immunogenic dendritic cells. Instead, they were converted to tolerogenic dendritic cells with strongly suppressed OVA-specific cytotoxic T cells' generation. Moreover, the production of OVA-specific IgG was tested in mice vaccinated with NP [OVA+DEX] . The findings strongly support that NPs loaded with both antigens (OVA) and DEX are useful in inducing antigen-specific immune tolerance, key for the treatment of several autoimmune diseases. 327 DEX can also be used to treat age-related macular degeneration diseases which involve inflammation and choroidal neovascularization. Liu et al. developed DEX-loaded NPs using poly(D,L-lactide-co-glycolide) and polyethylenimine on the surface of human umbilical vein endothelial cells (HUVEC) cells in combination with bevacizumab for impending intravitreal applications. These NPs showed an excellent antiangiogenic outcome and a robust inhibitory effect on VEGF secretion in HUVEC cells. Moreover, the treatment significantly reduced the number of blood vessels, and the leakage area of CNV was lessened in vivo. 328 More recently, PLGA loaded with DEX was used in low doses with a sustained release via an acellular osteochondral implant. This treatment resulted in a dual anti-catabolic and pro-anabolic effect, supportive of the functional integrity of adjacent graft and host tissue. It also reduced the inflammation caused by the iatrogenic injury (Figure 4) . 329 In summary, DEX-loaded PLGA NPs have potential in therapeutic applications.

7.2.4. Cyclodextrin Nanostructures. Cyclodextrins (CDs) are cyclic oligosaccharide-based NPs comprised of a lipophilic central cavity and hydrophilic outer surface. 330 CD molecules do not permeate lipophilic membranes because they contain quite a large number of hydrogen acceptors and donors. 331 CDs were first discovered nearly 100 years ago, and the first ACS Biomaterials Science & Engineering pubs.acs.org/journal/abseba Review patent on CD-based drug complexes was recorded in 1953. 332 They are increasingly used in the medical field mainly to increase the solubility of poorly soluble drugs and to increase their stability and biodegradability. CDs have been found as one of the potential candidates in the drug delivery field due to their ability to be physically, chemically, and biologically modified with small molecules/ drugs through the formation of insertion complexes. 333 CDs form noncovalent complexes between host molecules (hydrophobic drugs) and hydrophilic guest molecules and form intermolecular interactions such as weak van der Waals forces, electrostatic interactions, hydrogen bonds, and hydrophobic interactions. Water-soluble CD products have a low propensity to form aggregates and can naturally interact in water solutions. Recent developments have ensued in dramatic improvements in CD-based nanoformulations. For example, DEX-loaded CD NPs were used as eye drops for the treatment of noninfectious ophthalmic inflammatory diseases. 334 There are several similar DEX complexed CD nanoformulations that are established for the treatment of various inflammatory diseases. 335, 336 7.2.5. Hydrogels. Hydrogel-based drug delivery systems are commonly being used in medical treatments. 337, 338 Hydrogels have the finest tunable physical properties that offer spatial and sequential control in the release of several therapeutic agents, such as small-molecule drugs and genes, protecting them from degradation. 339, 340 They are 90% water and vastly porous, to house large amounts of drugs for delivery. 341 Present conventional treatment methods are plagued by concerns about systemic toxicity with using repeated dosing. 342 Hydrogels offer potential as the best drug delivery systems to minimize these disadvantages and improve the therapeutic benefits of drugs. 343 Hydrogels help as a platform for various physiochemical interfaces to encapsulate drugs/genes and ensure controlled drug release. 344 As cross-linked threedimensional frameworks of water-soluble polymers, hydrogels can be prepared from any water-soluble polymer. This allows packing a varied range of chemical and physical configurations to form microparticles, slabs, NPs, films, and coatings. 345 Hence, hydrogels are used in clinical practice or in experimental medicine for a vast range of applications, such as diagnostics, tissue engineering, wound healing, contact lenses, topical treatments, and regenerative medicine. 346 Other uses include the separation of biomolecules or cells, cellular immobilization, and barrier materials to regulate biological adhesions. There are several techniques available for the preparation of charges and hydrogel structures. 347 Hydrogels are commonly categorized as homopolymer, multipolymer, or copolymer, depending on the preparation methods. Based on the ionic charges, hydrogels can be classified into neutral, cationic, anionic, and ampholytic hydrogels. 343 Additionally, they can be classified into amorphous, hydrogen-bonded, and semicrystalline hydrogels based on their structure. 348 Hydrogels can release drugs because of diffusion, chemical and swelling control release systems, or environment responsive release systems. Despite numerous applications and advantages, hydrogels have some limitations. 349, 350 Because of their low tensile strength, many hydrogels are limited in their use within load-bearing environments, which can lead to an untimely dissolution or leak before reaching the target sites. However, these limitations are circumvented with various drug delivery applications, such as subcutaneous injection. 351 Some other hydrogels are adequately injectable or are topical applications and may not demand surgical implantation. 352 A homogeneous drug loading and multipurpose applications of hydrogels may be limited.

Here we focus on recent developments in the use of hydrogels for various anti-inflammatory diseases. For example, DEX-loaded hydrogels are increasingly used as platforms for local drug delivery to bone tissues. Scientists developed a DEXloaded [COCH 3 ]-RADARADARADARADA-[CONH 2 ] peptide comprised of hydrogels and successfully used them in the application of regenerative orthopedics. 106 Recently, investigators developed a calcium ion cross-linking and DEX sodium phosphate-containing alginate hybrid hydrogel to ACS Biomaterials Science & Engineering pubs.acs.org/journal/abseba Review extend drug release. These Ca 2+ /DEX/alginate hybrid hydrogels demonstrated excellent improvements in the drug bioavailability ( Figure 5 ). 353 A similar Ca 2+ /DEX supramolecular hydrogel was used as a therapeutic alternative for the treatment of noninfectious uveitis. 354 Recently, a silk-based hydrogel was developed by researchers to deliver DEX to the inner ear using an injectable silk−PEG hydrogel. 355 In summary, DEX-loaded hydrogels have the potential to translate from preclinical settings to the clinical setting. 7.2.6. Electrospun Nanofibers. Drug delivery systems applying nanofiber-based materials have been considered as a potential therapeutic strategy in tissue engineering over the past decade. 356, 357 Various technological approaches using electrospun nanofibers in combination with DEX have been proposed for treating various diseases, such as cancer, ocular, bone, and skin diseases. 358−361 Nanofibers, fabricated from different types of synthetic polymers, such as PCL, PLGA, PLA, and poly(ether sulfone), 282 and natural components (gelatin, chitosan, and collagen) are biocompatible in physiological conditions and possess potential characteristics for sustained drug release. 360, 362 The advantage of electrospun nanofibers as a carrier for DEX, as compared to other materials, is, first of all, their high surface-to-volume ratio, which increases the solubility of DEX and improves its efficacy. Furthermore, they possess tunable porosity and, most importantly, similarity to a natural extracellular matrix structure.

7.2.6.1. Combination of DEX with Other Stimulating Factors. DEX was applied in different kinds of nanofiber scaffolds as a single active molecule or in a combination with other stimulating factors. For instance, a dual delivery of BMP-2 and DEX electrospun nanofiber (PCL + PEG) has been proposed for treating critical-sized calvarial defects. The sequential release of both compounds has offered an efficient way of delivery and maintaining both compounds for at least 35 days, which results in strong osteogenesis responses in both in vitro and in vivo models ( Figure 6 ). 359 7.2.6.2. Controlled Release of DEX. An extended and sustained release of DEX from nanofiber scaffolds is one of the most desired options for tissue repair studies; however, sometimes, the embedded drugs may show undesired burst releases. To overcome these issues, the osteogenic properties of cells were analyzed on multilayer PLA pluronic P123 scaffolds loaded with DEX. DEX was included in the middle of a multilayered scaffold, which controlled its release and resulted in improved MSCs osteogenesis compared to singlelayer scaffolds. 97 Other studies suggest the use of nanofiber matrices loaded with DEX to stimulate the odontogenic differentiation of human dental pulp cells (HDPCs). The HDPCs are cultured on designed electrospun nanofiber matrices with bioactive glass NPs loaded with DEX for 14 days. This promotes odontogenesis of cells, including bone morphogenetic protein (BMPs), integrins, mTOR, and alkaline phosphatase, by stimulating molecular signaling pathways. 363 For an extended release of DEX, it has been shown that hybrid electrospun PCL nanofiber mats are made up of microbeads for the treatment of ocular diseases. 364 It has been reported that controlling electrospinning parameters modifies the duration of drug releases from nanofibers. Another option developed for ocular disease management is using selfassembled succinate DEX (DEX-SA) supramolecular hydrogel to extend precorneal retention. 365 This method introduces the gelling system with DEX-SA and lowers the cytotoxicity of DEX, maintains long-term stability, and shows excellent biocompatibility with intraocular tissues in rabbit eyes.

7.2.6.3. Inflammation Modulating Release of DEX. Inflammatory responses have also been modulated by DEX release from nanofibers. A study has developed a peptide amphiphile covalently conjugated to DEX through a labile hydrazone bond. Injection of this compound in vivo reduced the acute inflammatory response without systemic immune suppression. This technique is proposed to be used for treating different types of diseases, such as myocardial infarction. 366 Furthermore, silk fibroin nanofibers with embedded DEX, prepared by "green" electrospinning without any toxic agents, are considered one of the safest and most environment-friendly nanofibers. They have also been proposed as inflammatory modulating agents in vitro. The sustained release of DEX from these nanofibers has been shown to protect porcine endothelial cells from damage and apoptosis caused by lipopolysaccharide (LPS). 367 Furthermore, DEX is known to bind to astrocyte GRs and inhibit astrocyte proliferation. 368 A controlled release of DEX sodium phosphate loaded on chitosan NPs with gelatin electrospun nanofibers (PCL) was introduced as a promising therapy for the treatment of the nervous system during spinal cord injuries. 369 The developed scaffolds were mechanically stable with a controlled release of DEX and are proposed to be used as a bridging material to allow axons to grow through them, avoiding glial scar formation.

Therefore, electrospun nanofibers incorporated with drugs are promising alternative drug delivery systems for biomedical and nanotechnological applications with therapeutic potential. This technology is cost-effective, versatile, easy to fabricate, and easy to use in any kind of research facility.

7.3. Calcium Phosphate and Hydroxyapatite Structures. Bone-related diseases and injuries caused by trauma or congenital disorders pose a significant burden on health systems at both social and economic levels. Self-healing of the bones depends mainly on the size of the injury, the stability of the fracture site, and bone quality. 370 Many common diseases, such as diabetes, can significantly affect the quality and selfhealing potential of bones. Thus, there is an amassed need for the development of effective therapies for bone regeneration. Calcium phosphate-based bioceramics are the most prevalent bone substituents that closely resemble natural human bone. 371 However, these compositional similarities make it challenging to distinguish calcium phosphate fragments from native bone under imaging such as X-ray, magnetic resonance imaging, and computed tomography when screening the healing process. 372 Currently, radiologists use external contrast agents to improve the imaging contrast of calcium phosphate fragments, but these can affect their physicochemical properties and produce artifacts. Hence, improving calcium phosphate-based NPs and loading with anti-inflammatory drugs can enhance the quality of healing. Researchers have developed DEX-encapsulated calcium phosphate NPs along with collagen spongy complex frameworks for bone tissue engineering applications. These NPs presented virtuous biocompatibility and encouraged osteogenic differentiation of hMSCs when used for 3D culture of human bone marrow-derived MSCs. Further, in vivo implantation experiments demonstrate the synergistic effects of NPs for both osteogenic differentiation of hMSCs and bone regeneration. 114 A similar study was performed using bibasiccalcium phosphate NPs encapsulated with DEX for osteogenic differentiation of human MSCs. 373 DEX-encapsulated porous calcium phosphate/laponite cement significantly improved the proliferation of MG63 cells used for bone grafts. 374 Additionally, hydroxyapatite microspheres are recognized as excellent drug packing delivery vehicles. 375, 376 These NPs have biocompatibility for specific biomedical applications and can be prepared using an emulsion cross-link technique such as calcium ions as cross-linking agent. 377, 378 These provide an excellent application for pH-responsive drug delivery in bone tissue. For instance, DEX-encapsulated hollow hydroxyapatites were used to treat the odontogenic differentiation of human dental pulp cells. 379 In another study, a surface-fabricated hydroxyapatite framework was used for delivery of DEX and stromal cell-derived factor-1 for osteogenesis. In vitro cell culture experiments show that initial release of SDF-1 stimulated the migration of MSCs to the deep interior of the scaffold. Additionally, in vivo experiments show that cell-guided systems efficiently enhance the early cell recruitment and vascularization for cell-free bone tissue engineering applications. 98 7.4. Silica Nanoparticles. Silica NPs, especially mesoporous silica NPs, have modernized the field of drug delivery systems. 380, 381 Due to their porous configuration, huge surface area, large pore volume, and selective surface functionality, silica NPs enable a high therapeutic drug loading especially with hydrophobic water-insoluble drugs. 380, 382 The silica matrix framework protects loaded drugs from degradation by enzymes. Additionally, silica NPs help in prolonged sustained drug release by stopping burst releases using pore-gating approaches. 383, 384 Furthermore, silica NPs can be modified with stimuli-responsive groups, polymers, protein, or targeting ligands that can further selectively direct them to diseased sites. Silica-based NPs can easily be administered intravenously to resolve the side effects associated with other routes of delivery. Mesoporous silica-based NPs were first manufactured by 385 and are being used for a variety of anti-inflammatory diseases. For example, researchers developed covalently grafted DEX into the pore walls of fully oxidized mesoporous silicon particles (pSiO2-COO-Dex) and evaluated their pharmacological effects in ARPE19 cells. Further, in vivo efficacy was evaluated in both rabbit eyes and human VEGF-induced retinal models for vascular permeability. 386 In another study, DEX-loaded silica NPs significantly enhanced the in vitro proliferation and osteogenic differentiation of rat bone marrow-derived MSCs. Additionally, in vivo experiments report significant new bone formation abilities. 387 Furthermore, BMP-2 peptide decorated DEX-loaded mesoporous silica NPs improved osteogenic differentiation of bone MSCs (Figure 7) . 388 In summary, silica-based DEX NPs show improved potential for the treatment of several inflammatory diseases.

Nanomedicine is revolutionizing advances in the diagnosis and treatment of several diseases. Numerous nanoparticle-based formulations have already been industrialized and play an imperative role in the management of diseases. Nanoformulations that combine therapeutic agents, molecular targeting, and imaging capabilities act as the next generation of disease treatment options. There are numerous advantages in using nanomaterials for drug delivery: (i) they increase the concentration of drug in the disease site; (ii) they allow a sustained and slow release of the drug, which improves its efficacy; (iii) they solve issues related to the poor solubility and bioavailability of drugs; and (iv) they are small, nontoxic, biodegradable, and biocompatible. DEX is a glucocorticoid family of steroids used as an anti-inflammatory, immunosuppressive, and anticancer drug in the clinic. One of the major complications with this drug is its low solubility in water, 

Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone

Jr Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis

Dexamethasone increases cisplatin-loaded nanocarrier delivery and efficacy in metastatic breast cancer by normalizing the tumor microenvironment

Dexamethasone decreases the autotaxin-lysophosphatidate-inflammatory axis in adipose tissue: implications for the metabolic syndrome and breast cancer

Single dose of dexamethasone is not associated with postoperative recurrence and mortality in breast cancer patients: a propensity-matched cohort study

S1606 safety and efficacy of combination of selinexor, daratumumab, and dexamethasone (SDD) in patients with multiple myeloma (MM) previously exposed to proteasome inhibitors and immunomodulatory drugs

Daratumumab (DARA) maintenance therapy improves depth of response and results in durable progression-free survival (PFS) following Dara plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): update of the Lyra study

Oral selinexor−dexamethasone for triple-class refractory multiple myeloma

Controversial roles for dexamethasone in glioblastoma−Opportunities for novel vascular targeting therapies

Dexamethasone in glioblastoma multiforme therapy: mechanisms and controversies

Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib

Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia

Neuroanatomical abnormalities related to dexamethasone ACS Biomaterials Science & Engineering pubs.acs.org/journal/abseba Review

Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways

Dexamethasone alleviates pemetrexed-induced senescence in non-small-cell lung cancer

Dexamethasone suppresses the growth of human non-small cell lung cancer via inducing estrogen sulfotransferase and inactivating estrogen

Dexamethasone on postoperative gastrointestinal motility: A placebo-controlled, double-blinded, randomized controlled trial

Possible dose dependent effect of perioperative dexamethasone and laparoscopic surgery on the postoperative systemic inflammatory response and complications following surgery for colon cancer

Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

Use of lenalidomide may surmount the adverse prognosis induced by renal impairment in patients (pts) with relapsed/refractory multiple myeloma (MM)

Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide. British journal of cancer

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Dexamethasone induces docetaxel and cisplatin resistance partially through up-regulating Kruppel-like factor 5 in triple-negative breast cancer

Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial

SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells

Dexamethasone loaded multi-layer poly-l-lactic acid/pluronic P123 composite electrospun nanofiber scaffolds for bone tissue engineering and drug delivery

Surface-decorated hydroxyapatite scaffold with ondemand delivery of dexamethasone and stromal cell derived factor-1 for enhanced osteogenesis

The synergistic effect of nano-hydroxyapatite and dexamethasone in the fibrous delivery system of gelatin and poly (l-lactide) on the osteogenesis of mesenchymal stem cells

Electrically responsive microreservoires for controllable delivery of dexamethasone in bone tissue engineering

Poly-l-lactic acid scaffold incorporated chitosan-coated mesoporous silica nanoparticles as pH-sensitive composite for enhanced osteogenic differentiation of human adipose tissue stem cells by dexamethasone delivery. Artificial cells, nanomedicine, and biotechnology

Hydroxyapatite/polylactide biphasic combination scaffold loaded with dexamethasone for bone regeneration

An efficient functionalization of dexamethasone-loaded polymeric scaffold with [3-(2, 3-epoxypropoxy)-propyl]-trimethoxysilane coupling agent for bone regeneration: Synthesis, characterization, and in vitro evaluation

Recent advances in the application of mesoporous silica-based nanomaterials for bone tissue engineering

Electrophoretic deposition of dexamethasone-loaded mesoporous silica nanoparticles onto poly (Llactic acid)/poly (ε-caprolactone) composite scaffold for bone tissue engineering

Bone tissue engineering in a perfusion bioreactor using dexamethasone-loaded peptide hydrogel

Dexamethasone release from within engineered cartilage as a chondroprotective strategy against interleukin-1α

Role of dexamethasone in the long-term functional maturation of MSC-laden hyaluronic acid hydrogels for cartilage tissue engineering

Synthesis, physicochemical, rheological and in-vitro characterization of double-crosslinked hyaluronic acid hydrogels containing dexamethasone and PLGA/ dexamethasone nanoparticles as hybrid systems for specific medical applications

Development and characterization of carbohydratebased thermosensitive hydrogels for cartilage tissue engineering

Dexamethasone releasing chitosan scaffold for cartilage development

Adapted dexamethasone delivery polyethylene oxide and poly (ε-caprolactone) construct promote mesenchymal stem cells chondrogenesis. Artificial cells, nanomedicine, and biotechnology

Cell surface engineering to enhance mesenchymal stem cell migration toward an SDF-1 gradient

Preparation of dexamethasone-loaded biphasic calcium phosphate nanoparticles/collagen porous composite scaffolds for bone tissue engineering

Loadbearing PTMC-beta tri-calcium phosphate and dexamethasone biphasic composite microsphere scaffolds for bone tissue engineering

Composite PLA/PEG/nHA/dexamethasone scaffold prepared by 3D printing for bone regeneration

Controlled dexamethasone delivery via double-walled microspheres to enhance long-term adipose tissue retention

Magnetic hyaluronic acid nanospheres via aqueous Diels−Alder chemistry to deliver dexamethasone for adipose tissue engineering

Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation

Molecular mechanisms regulating myogenic determination and differentiation

Dexamethasone regulates the actions of endogenous insulin-like growth factor-II during myogenic differentiation

Dexamethasone treatment at the myoblast stage enhanced C2C12 myocyte differentiation

Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global healthThe latest 2019 novel coronavirus outbreak in Wuhan

Mechanism of Anosmia Caused by Symptoms of COVID-19 and Emerging Treatments

The role of Nanotechnology in current COVID-19 outbreak

Vaccines in Clinical Trials and their Mode of Action for Immunity against the Virus

Nabipour, I. COVID-19 cytokine storm: The anger of inflammation

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells

Dexamethasone for the treatment of coronavirus disease (COVID-19): a review

CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

Vitamin E at a high dose as an anti-ferroptosis drug and not just a supplement for COVID-19 treatment

Treatment for severe acute respiratory distress syndrome from COVID-19

Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial

Prednisone and methylprednisolone disposition in the lung

Corticosteroids Administration Following COVID-19-induced Acute Respiratory Distress Syndrome. Is it harmful or Life-saving?

Dexamethasone in hospitalized patients with Covid-19

Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Adjuvant corticosteroid therapy for critically ill patients with COVID-19

Short Course Corticosteroids in Hospitalized Patients with COVID-19

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease

A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia

Inflammation suppression by dexamethasone via inhibition of CD147-mediated NF-κB pathway in collagen-induced arthritis rats

The immunology of COVID-19: is immune modulation an option for treatment?

Inferring molecular mechanisms of dexamethasone therapy in severe COVID-19 from existing transcriptomic data

The role of ACE2, angiotensin-(1−7) and Mas1 receptor axis in glucocorticoid-induced intrauterine growth restriction

Glucocorticoid induction of angiotensin converting enzyme production from bovine endothelial cells in culture and rat lung in vivo

Stimulatory effect of dexamethasone on angiotensin-converting enzyme in neonatal rat cardiac myocytes. Braz

The World Against Versatile SARS-Cov-2 Nanomachines: Mythological or Reality? Current Stem Cell Research & Therapy

Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and Severe Hypoxemia: The COVID STEROID 2 randomized trial

Molecular mechanisms of glucocorticoids action: implications for treatment of rhinosinusitis and nasal polyposis

How does dexamethasone therapy work in severe COVID-19?

Nanoparticles targeting STATs in cancer therapy

Monoterpenes modulating autophagy: A review study

Lipid-Based Nanoparticles for Drug-Delivery Systems. Nanocarriers for Drug Delivery

Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances

Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis

Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment

Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic

Recent advances in lipid-based nanodrug delivery systems in cancer therapy

A Systematic Study of Cu Nanospheres Embedded in Non-ionic Surfactant-Based Vesicle: Photocatalytic Efficiency and In Vivo Imaging Study

Development and characterization of nanostructured lipid carriers based chitosan thermosensitive hydrogel for delivery of dexamethasone

Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an in vivo model

Lipid/alginate nanoparticle-loaded in situ gelling system tailored for dexamethasone nasal delivery

Sialic acid-modified dexamethasone lipid calcium phosphate gel core nanoparticles for target treatment of kidney injury

Neutrophil-Mediated Delivery of Dexamethasone Palmitate-Loaded Liposomes Decorated with a Sialic Acid Conjugate for Rheumatoid Arthritis Treatment

Peptide-targeted liposomal delivery of dexamethasone for arthritis therapy

A Novel Liposomal Dexamethasone Palmitate Formulation and Anti-inflammatory Effects on Mice

Liposome-incorporated dexamethasone palmitate: Chemical and physical properties

Dexamethasone Incorporating Liposomes: Effect of Lipid Composition on Drug Trapping Efficiency and Vesicle Stability

A novel dexamethasone-loaded liposome alleviates rheumatoid arthritis in rats

Liposomal dexamethasone-moxifloxacin nanoparticle combinations with collagen/gelatin/alginate hydrogel for corneal infection treatment and wound healing

Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid-octadecylamine conjugate

Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma

Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia

Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo

Prolonged Duration Local Anesthesia Using Liposomal Bupivacaine Combined With Liposomal Dexamethasone and Dexmedetomidine

Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases

Facile and Versatile Strategy for Construction of Anti-Inflammatory and Antibacterial Surfaces with Polydopamine-Mediated Liposomes Releasing Dexamethasone and Minocycline for Potential Implant Applications

Establishing Liposome-Immobilized Dexamethasone-Releasing PDMS Membrane for the Cultivation of Retinal Pigment Epithelial Cells and Suppression of Neovascularization

Effect of a liposomal hyaluronic acid gel loaded with dexamethasone in a guinea pig model after manual or motorized cochlear implantation

The effect of dexamethasone/cell-penetrating peptide nanoparticles on gene delivery for inner ear therapy

Nanocarriers and nanoparticles for skin care and dermatological treatments

Polymeric micelles as cutaneous drug delivery system in normal skin and dermatological disorders

Formulation and comparative in vitro evaluation of various dexamethasone-loaded pH-sensitive polymeric nanoparticles intended for dermal applications

Localization of dexamethasone within dendritic core-multishell (CMS) nanoparticles and skin penetration properties studied by multi-frequency electron paramagnetic resonance (EPR) spectroscopy

Dexamethasone-loaded biopolymeric nanoparticles promote gingival fibroblasts differentiation

Potential of rhBMP-2 and dexamethasone-loaded Zein/PLLA scaffolds for enhanced in vitro osteogenesis of mesenchymal stem cells

Biomimetic and biodegradable cellulose acetate scaffolds loaded with dexamethasone for bone implants

Dexamethasone-loaded Polymeric Nanoconstructs for Monitoring and Treating Inflammatory Bowel Disease

Preliminary characterization of dexamethasone-loaded cross-linked hyaluronic acid films for topical ocular therapy

Constructing an Anisotropic Triple-Pass Tubular Framework within a Lyophilized Porous Gelatin Scaffold Using Dexamethasone-Loaded Functionalized Whatman Paper To Reinforce Its Mechanical Strength and Promote Osteogenesis

Reactive oxygen speciesresponsive dexamethasone-loaded nanoparticles for targeted treatment of rheumatoid arthritis via suppressing the iRhom2/TNF-α/ BAFF signaling pathway

Controlled release of dexamethasone from poly(vinyl alcohol) hydrogel

Dexamethasone-loaded injectable silk-polyethylene glycol hydrogel alleviates cisplatin-induced ototoxicity

Dexamethasone-loaded chitosan-based genipin-cross-linked hydrogel for prevention of cisplatin induced ototoxicity in Guinea pig model

An Injectable Click-Crosslinked Hydrogel that Prolongs Dexamethasone Release from Dexamethasone-Loaded Microspheres

Ocular Permeation and Sustained Anti-inflammatory Activity of Dexamethasone from Kaolin Nanodispersion Hydrogel System

Combination of dexamethasone and Avastin(®) by supramolecular hydrogel attenuates the inflammatory corneal neovascularization in rat alkali burn model

Intra-Articular Injection of Cross-Linked Hyaluronic Acid-Dexamethasone Hydrogel Attenuates Osteoarthritis: An Experimental Study in a Rat Model of Osteoarthritis

Longterm effects and potential limits of intratympanic dexamethasoneloaded hydrogels combined with dexamethasone-eluting cochlear electrodes in a low-insertion trauma Guinea pig model

Effects of sustained release dexamethasone hydrogels in hearing preservation cochlear implantation

Biodegradable hyaluronic acid hydrogels to control release of dexamethasone through aqueous Diels-Alder chemistry for adipose tissue engineering

pH-Responsive guar gum hydrogels for controlled delivery of dexamethasone to the intestine

Covalent incorporation and controlled release of active dexamethasone from injectable polyethylene glycol hydrogels

Development of chitosan nanoparticles coated with hyaluronic acid for topical ocular delivery of dexamethasone

The potential application of hyaluronic acid coated chitosan nanoparticles in ocular delivery of dexamethasone

Synthesis and Characterization of Poly(2-hydroxyethylmethacrylate) Contact Lenses Containing Chitosan Nanoparticles as an Ocular Delivery System for Dexamethasone Sodium Phosphate

Local anaesthetic pain relief therapy: In vitro and in vivo evaluation of a nanotechnological formulation co-loaded with ropivacaine and dexamethasone

Dexamethasone loaded PLGA nanoparticles for potential local treatment of oral precancerous lesions

Sequential transfection of RUNX2/SP7 and ATF4 coated onto dexamethasone-loaded nanospheres enhances osteogenesis

Physicochemical and mechanical properties of freeze cast hydroxyapatite-gelatin scaffolds with dexamethasone loaded PLGA microspheres for hard tissue engineering applications

Towards a better understanding of the different release phases from PLGA microparticles: Dexamethasoneloaded systems

PLGA Implants containing vancomycin and dexamethasone: development, characterization and bactericidal effects

Controlled release of dexamethasone sodium phosphate with biodegradable nanoparticles for preventing experimental corneal neovascularization

Intra-Articular Formulation of GE11-PLGA Conjugate-Based NPs for Dexamethasone Selective Targeting-In Vitro Evaluation

In-situ forming PLGA implants for intraocular dexamethasone delivery

Intracochlear PLGA based implants for dexamethasone release: Challenges and solutions

Optimising the controlled release of dexamethasone from a new generation of PLGA-based microspheres intended for intravitreal administration

Design and in vitro evaluation of biocompatible dexamethasone-loaded nanoparticle dispersions, obtained from nano-emulsions, for inhalatory therapy

Prediction of dexamethasone release from PLGA microspheres prepared with polymer blends using a design of experiment approach

Fabrication of chitosan/ polyvinylpyrrolidone hydrogel scaffolds containing PLGA microparticles loaded with dexamethasone for biomedical applications

Topical dexamethasone γ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema

Topical dexamethasone-cyclodextrin nanoparticle eye drops for non-infectious Uveitic macular oedema and vitritis -a pilot study

Investigation of Combined Cyclodextrin and Hydrogel Formulation for Ocular Delivery of Dexamethasone Acetate by Means of Experimental Designs

Self-assembled supramolecular hydrogel based on PCL-PEG-PCL triblock copolymer and γ-cyclodextrin inclusion complex for sustained delivery of dexamethasone

Hyaluronic acid and beta cyclodextrins films for the release of corneal epithelial cells and dexamethasone

A dual-delivery system of pH-responsive chitosan-functionalized mesoporous silica nanoparticles bearing BMP-2 and dexamethasone for enhanced bone regeneration

Long-Term in vivo Release Profile of Dexamethasone-Loaded Silicone Rods Implanted Into the Cochlea of Guinea Pigs

Feasibility Study of Mesoporous Silica Particles for Pulmonary Drug Delivery: Therapeutic Treatment with Dexamethasone in a Mouse Model of Airway Inflammation

Inducing Macrophages M2 Polarization by Dexamethasone Laden Mesoporous Silica Nanoparticles from Titanium Implant Surface for Enhanced Osteogenesis

Corneal permeation properties of a charged lipid nanoparticle carrier containing dexamethasone

A Lipid Micellar System Loaded with Dexamethasone Palmitate Alleviates Rheumatoid Arthritis

Effect of formulation and processing variables on dexamethasone entrapment and release of niosomes

On the use of dexamethasone-loaded liposomes to induce the osteogenic differentiation of human mesenchymal stem cells

Liposomal dexamethasone−moxifloxacin nanoparticles combinations with collagen/gelatin/alginate hydrogel for corneal infection treatment and wound healing

Liposomal nanotherapeutics in cancer treatment

Liposomal formulations in clinical use: an updated review

Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date

Advances and Challenges of Liposome Assisted Drug Delivery

Aghaei-Afshar, A. Photodynamic therapy for leishmaniasis: recent advances and future trends

Overview of preparation methods of polymeric and lipid-based (niosome, solid lipid, liposome) nanoparticles: A comprehensive review

Dexamethasone Loaded Liposomes by Thin-Film Hydration and Microfluidic Procedures: Formulation Challenges

Improving the anti-inflammatory efficacy of dexamethasone in the treatment of rheumatoid arthritis with polymerized stealth liposomes as a delivery vehicle

Solid lipid nanoparticles: a modern formulation approach in drug delivery system

Drug targeting using solid lipid nanoparticles

Solid lipid based nanocarriers: an overview

Microwave-assisted formulation of solid lipid nanoparticles loaded with non-steroidal anti-inflammatory drugs

Solid lipid nanoparticles for the controlled delivery of poorly water soluble nonsteroidal anti-inflammatory drugs

Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Archives of pharmacal research

Recent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challenges

Lipid Nanoparticle Technology for Delivering Biologically Active Fatty Acids and Monoglycerides

Enhanced In Vitro Antimicrobial Activity of Polymyxin B−Coated Nanostructured Lipid Carrier Containing Dexamethasone Acetate

Lipid nanocapsules: a new platform for nanomedicine

Recent Trends of the Bio-Inspired Nanoparticles in Cancer Theranostics

Budai-Szucs, M. Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use

Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease

Chitosan Coated Nanostructured Lipid Carriers Containing Dexamethasone Acetate

Hydrogel containing dexamethasone-loaded nanocapsules for cutaneous administration: preparation, characterization, and in vitro drug release study

Lipid/alginate nanoparticle-loaded in situ gelling system tailored for dexamethasone nasal delivery

Cationic polymeric nanocapsules as a strategy to target dexamethasone to viable epidermis: skin penetration and permeation studies

Dexamethasone-Loaded Lipomers: Development, Characterization, and Skin Biodistribution Studies

Polymeric nanoparticles: Promising platform for drug delivery

Polymer Nanoparticles for Drug Delivery Applications in Cancer and Neurodegenerative Disorder Therapies

Polymeric Nanoparticles that Combine Dexamethasone and Naproxen for the Synergistic Inhibition of Il12b Transcription in Macrophages

Green synthesis of strontium nanoparticles self-assembled in the presence of carboxymethyl cellulose: an in vivo imaging study

Plant virus nanoparticles: novel and robust nanocarriers for drug delivery and imaging

Plasmid DNA delivery into hepatocytes using a multifunctional nanocarrier based on sugar-conjugated polyethylenimine

Delivery of plasmid encoding interleukin-12 gene into hepatocytes by conjugated polyethylenimine-based nanoparticles

Tetraiodothyroacetic acid-conjugated polyethylenimine for integrin receptor mediated delivery of the plasmid encoding IL-12 gene

Targeted double domain nanoplex based on galactosylated polyethylenimine enhanced the delivery of IL-12 plasmid

Recent advances in polymeric drug delivery systems

Polymers for drug delivery systems

Polymeric Nanoparticles for Drug Delivery

Responsive polymer nanoparticles for drug delivery applications. Stimuli Responsive Polymeric Nanocarriers for

Treatment of experimental autoimmune encephalomyelitis by codelivery of disease associated Peptide and dexamethasone in acetalated dextran microparticles

Multifunctional polymeric nanoplatforms for brain diseases diagnosis, therapy and theranostics

Interleukin-12 plasmid DNA delivery using l-thyroxine-conjugated polyethylenimine nanocarriers

Non-toxic polymer nanovectors for improved delivery of dexamethasone

Encapsulation of polyprodrugs enables an efficient and controlled release of dexamethasone

A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies

3D printed lactose-crosslinked gelatin scaffolds as a drug delivery system for dexamethasone

Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: Inserts, patches, wafers, and implants

Gelatine-based drug-eluting bandage contact lenses: Effect of PEGDA concentration and manufacturing technique

Recent Trends in Applications of Nano-Drug Delivery Systems. Handbook of Lung Targeted Drug Delivery Systems: Recent Trends and Clinical Evidences

Recent developments in functionalized polymer nanoparticles for efficient drug delivery system

Advanced nanomedicines for the treatment of inflammatory diseases

Polymeric nanoparticles loaded with dexamethasone or α-tocopheryl succinate to prevent cisplatin-induced ototoxicity

Dexamethasone loaded nanoparticles exert protective effects against Cisplatin-induced hearing loss by systemic administration

Evaluation of anti-inflammatory impact of dexamethasone-loaded PCL-PEG-PCL micelles on endotoxin-induced uveitis in rabbits

Chitosan hydrogels incorporating colloids for sustained drug delivery

Chitosan-based advanced materials for docetaxel and paclitaxel delivery: Recent advances and future directions in cancer theranostics

Chitosan: A versatile bio-platform for breast cancer theranostics

Development of chitosan nanoparticles coated with hyaluronic acid for topical ocular delivery of dexamethasone

In vitro release and characterization of chitosan films as dexamethasone carrier

Development and characterization of nanostructured lipid carriers based chitosan thermosensitive hydrogel for delivery of dexamethasone

Effects of drying methods on the preparation of dexamethasone-loaded chitosan microspheres

Mussel-inspired adhesive and transferable free-standing films by self-assembling dexamethasone encapsulated BSA nanoparticles and vancomycin immobilized oxidized alginate

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

Silk fibroin hydrogel/dexamethasone sodium phosphate loaded chitosan nanoparticles as a potential drug delivery system

Functional chitosan oligosaccharide nanomicelles for topical ocular drug delivery of dexamethasone

Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease

Temporal-controlled dexamethasone releasing chitosan nanoparticle system enhances odontogenic differentiation of stem cells from apical papilla

Mucoadhesive dexamethasone-glycol chitosan nanoparticles for ophthalmic drug delivery

Mucoadhesive cholesterol-chitosan self-assembled particles for topical ocular delivery of dexamethasone

Polylactide (PLA)-based nanocomposites

A Perspective on Polylactic Acid-Based Polymers Use for Nanoparticles Synthesis and Applications

Effect of drug carrier melting points on drug release of dexamethasone-loaded microspheres. Tissue Engineering and Regenerative Medicine

Dexamethasone-diclofenac loaded polylactide nanoparticles: Preparation, release and anti-inflammatory activity

Systematic Study of NaF Nanoparticles in Micelles loaded on Polylactic Acid Nanoscaffolds: In Vitro Efficient Delivery

Lactic Acid) Nanoparticle Size Reduction Increases Its Immunotoxicity

Topoisomerase inhibitors: Pharmacology and emerging nanoscale delivery systems

Hydrolytic Degradation and Erosion of Polyester Biomaterials

A single dose of dexamethasone encapsulated in polyethylene glycol-coated polylactic acid nanoparticles attenuates cisplatin-induced hearing loss following round window membrane administration

Functional polymeric nanoparticles for dexamethasone loading and release

PLGA Nanoparticles in Drug Delivery: The State of the Art

PLGA-Based Nanoparticles in Cancer Treatment

Dexamethasone (DXM)-Coated Poly (lacticco-glycolic acid)(PLGA) Microneedles as an Improved Drug Delivery System for Intracochlear Biodegradable Devices

Substance P/ dexamethasone-encapsulated PLGA scaffold fabricated using supercritical fluid process for calvarial bone regeneration

A simple coating method of PDMS microchip with PTFE for synthesis of dexamethasone-encapsulated PLGA nanoparticles

Encapsulation of dexamethasone into biodegradable polymeric nanoparticles

Induction of antigen-specific immune tolerance using biodegradable nanoparticles containing antigen and dexamethasone

Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications

Sustained low-dose dexamethasone delivery via a PLGA microsphere-embedded agarose implant for enhanced osteochondral repair

Cyclodextrins in delivery systems

Cyclodextrins in drug delivery

Nasal absorption enhancement strategies for therapeutic peptides: an in vitro study using cultured human nasal epithelium

Progress in delivery of siRNAbased therapeutics employing nano-vehicles for treatment of prostate cancer

Treatment of non-infectious ophthalmic inflammatory diseases with 1.5% dexamethasone γ-cyclodextrin nanoparticle eye drops

A water-soluble, mucoadhesive quaternary ammonium chitosanmethyl-β-cyclodextrin conjugate forming inclusion complexes with dexamethasone

Dexamethasone loaded bilayered 3D tubular scaffold reduces restenosis at the anastomotic site of tracheal replacement: in vitro and in vivo assessments

Status and future scope of plant-based green hydrogels in biomedical engineering

Engineered adipose tissue from human mesenchymal stem cells maintains predefined shape and dimension: implications in soft tissue augmentation and reconstruction

Designing hydrogels for controlled drug delivery

Progress in natural compounds/ siRNA co-delivery employing nanovehicles for cancer therapy

Hydrogels and Their Applications in Targeted Drug Delivery

Hydrogels in drug delivery: Progress and challenges

New Horizons in Hydrogels for Methotrexate Delivery

Glycol chitosan/oxidized hyaluronic acid hydrogel film for topical ocular delivery of dexamethasone and levofloxacin

Hydrogel-mediated local delivery of dexamethasone reduces neuroinflammation after traumatic brain injury

Hydrogel: Preparation, Characterization and Applications

Recent progress in sodium alginate based sustainable hydrogels for environmental applications

A mini review on hydrogels classification and recent developments in miscellaneous applications

Hydrogel: Preparation, characterization, and applications: A review

Advances in Engineering Hydrogels

Dexamethasone-loaded, injectable pullulan-poly (ethylene glycol) hydrogels for bone tissue regeneration in chronic inflammatory conditions

Calcium ion cross-linking alginate/dexamethasone sodium phosphate hybrid hydrogel for extended drug release

Calcium ion coordinated dexamethasone supramolecular hydrogel as therapeutic alternative for control of non-infectious uveitis

Inner ear delivery of dexamethasone using injectable silk-polyethylene glycol (PEG) hydrogel

Nanotechnological strategies for osteoarthritis diagnosis, monitoring, clinical management, and regenerative medicine: recent advances and future opportunities

Electrospun nanocarriers for delivering natural products for cancer therapy

Controlling drug delivery using nanosheet-embedded electrospun fibers for efficient tumor treatment

Controlled dual delivery of BMP-2 and dexamethasone by nanoparticle-embedded electrospun nanofibers for the efficient repair of critical-sized rat calvarial defect

Preparation and evaluation of dexamethasoneloaded electrospun nanofiber sheets as a sustained drug delivery system

Ocular biocompatibility of dexamethasone acetate loaded poly (ε-caprolactone) nanofibers

Design and characterization of dexamethasone-loaded poly (glycerol sebacate)-poly caprolactone/gelatin scaffold by coaxial electro spinning for soft tissue engineering

Delivery of dexamethasone from bioactive nanofiber matrices stimulates odontogenesis of human dental pulp cells through integrin/BMP/mTOR signaling pathways

Hybrid electrospun polycaprolactone mats consisting of nanofibers and microbeads for extended release of dexamethasone

Supramolecular nanofibers of dexamethasone derivatives to form hydrogel for topical ocular drug delivery

Controlled release of dexamethasone from peptide nanofiber gels to modulate inflammatory response

Dexamethasone loaded core− shell SF/PEO nanofibers via green electrospinning reduced endothelial cells inflammatory damage

Glucocorticoid regulation of astrocytic fate and function

The controlled release of dexamethasone sodium phosphate from bioactive electrospun PCL/gelatin nanofiber scaffold

Calcium Phosphate Nanoparticles for Therapeutic Applications in Bone Regeneration

Promoted angiogenesis and osteogenesis by dexamethasone-loaded calcium phosphate nanoparticles/collagen composite scaffolds with microgroove networks

Theranostic Calcium Phosphate Nanoparticles With Potential for Multimodal Imaging and Drug Delivery

Preparation of dexamethasone-loaded calcium phosphate nanoparticles for the osteogenic differentiation of human mesenchymal stem cells

Dexamethasone loaded Laponite®/porous calcium phosphate cement for treatment of bone defects

Porous hydroxyapatite scaffold with threedimensional localized drug delivery system using biodegradable microspheres

The impact of the ionic cross-linking mode on the physical and in vitro dexamethasone release properties of chitosan/hydroxyapatite beads

Fabrication and characterization of hydroxyapatite/sodium alginate/chitosan composite microspheres for drug delivery and bone tissue engineering

Porous hollow hydroxyapatite microspheres synthesized by spray pyrolysis using a microalga template: preparation, drug delivery, and bioactivity

Dexamethasone-loaded hollow hydroxyapatite microsphere promotes odontogenic differentiation of human dental pulp cells in vitro

Mesoporous silica nanoparticles for drug and gene delivery

Multifunctional Mesoporous Silica Nanoparticles as a Universal Platform for Drug Delivery

XXX, XXX−XXX chemical properties to enhanced dissolution of poorly water-soluble drugs

Mesoporous silica nanoparticles: synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery

Smart mesoporous silica nanoparticles for controlled-release drug delivery

Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism

Controlled Release of Dexamethasone From an Intravitreal Delivery System Using Porous Silicon Dioxide

Incorporation of dexamethasone-loaded mesoporous silica nanoparticles into mineralized porous biocomposite scaffolds for improving osteogenic activity

BMP-2 Derived Peptide and Dexamethasone Incorporated Mesoporous Silica Nanoparticles for Enhanced Osteogenic Differentiation of Bone Mesenchymal Stem Cells